Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enhanced Platelet-Rich Fibrin
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
- Administration
- Local
01
Overview
Enhanced Platelet-Rich Fibrin (E-PRF) is an autologous, second-generation platelet concentrate and biological scaffold derived from a patient's own blood. It is produced through a specialized centrifugation protocol designed to optimize the concentration of platelets, leukocytes, and endogenous growth factors within a dense fibrin matrix. Developed and investigated at the University of Alabama at Birmingham, E-PRF serves as a biological carrier for therapeutic proteins, such as recombinant human bone morphogenetic protein-2 (rhBMP-2), in regenerative medicine. The scaffold functions by providing a sustained-release platform for essential growth factors, including vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and platelet-derived growth factor (PDGF), which collectively promote angiogenesis, cell migration, and tissue healing. In oral and maxillofacial surgery, E-PRF is being evaluated for its ability to enhance bone regeneration and improve the delivery kinetics of osteoinductive agents compared to traditional synthetic carriers like absorbable collagen sponges.
- Other names
- Enhanced PRFPlatelet-Rich Fibrin
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)PDGFR (PDGFR family)TGFBR (TGF-beta receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on Enhanced Platelet-Rich Fibrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enhanced Platelet-Rich Fibrin.